Bristol Myers Squibb BMY

Bristol Myers Squibb is facing significant financial hurdles, with a projected revenue decline of approximately $10 billion due to generics following a patent cliff. Despite reporting strong quarterly earnings, driven by a surge in Eliquis sales, the company's high debt levels and upcoming patent expirations raise concerns about long-term stability. In response, Bristol Myers is launching new drugs and has made a licensing agreement worth $15 billion, alongside integrating AI initiatives to enhance efficiency. The company anticipates shifts in its revenue model, partly mitigated by growth in its oncology drug Opdivo, while also navigating legal challenges surrounding delays in its cancer drug Breyanzi and awaiting critical FDA decisions on key therapeutics.